43 research outputs found

    Land Use Guidance System PLanning for Environmental Quality

    Get PDF

    Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for in vivo Evaluation of Drug Regimens

    Get PDF
    Human immune system mice are highly valuable for in vivo dissection of human immune responses. Although they were employed for analyzing tuberculosis (TB) disease, there is little data on the spatial organization and cellular composition of human immune cells in TB granuloma pathology in this model. We demonstrate that human immune system mice, generated by transplanted human fetal liver derived hematopoietic stem cells develop a continuum of pulmonary lesions upon Mycobacterium tuberculosis aerosol infection. In particular, caseous necrotic granulomas, which contribute to prolonged TB treatment time, developed, and had cellular phenotypic spatial-organization similar to TB patients. By comparing two recommended drug regimens, we confirmed observations made in clinical settings: Adding Moxifloxacin to a classical chemotherapy regimen had no beneficial effects on bacterial eradication. We consider this model instrumental for deeper understanding of human specific features of TB pathogenesis and of particular value for the pre-clinical drug development pipeline

    31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

    Get PDF
    Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

    Advantages of using the QIAshredder instead of restriction digestion to prepare DNA for droplet digital PCR

    No full text
    The viscosity of genomic DNA can interfere with digital PCR systems that partition samples into oil droplets or microfluidic wells. Restriction digestion may reduce the viscosity, but the process is labor-intensive, and the buffer can alter the conditions for PCR. DNA fragmentation using the QIAshredder (a biopolymer spin column) is faster, may result in more predictable and uniformly-sized fragments, and avoids the need for restriction buffers that can inhibit downstream PCR. In 10 separate head-to-head experiments comparing aliquots of DNA processed using the QIAshredder to those digested with RsaI or BsaJI prior to droplet digital PCR, we found that the copy numbers measured from the QIAshredded DNA tended to be greater than those measured from the digested DNA (average of 1.35-fold compared with BsaJI; P &lt; 0.0001), even for inputs as high as 1.8 ÎĽg or dilution down to the single copy level

    Advantages of using the QIAshredder instead of restriction digestion to prepare DNA for droplet digital PCR

    No full text
    The viscosity of genomic DNA can interfere with digital PCR systems that partition samples into oil droplets or microfluidic wells. Restriction digestion may reduce the viscosity, but the process is labor-intensive, and the buffer can alter the conditions for PCR. DNA fragmentation using the QIAshredder (a biopolymer spin column) is faster, may result in more predictable and uniformly-sized fragments, and avoids the need for restriction buffers that can inhibit downstream PCR. In 10 separate head-to-head experiments comparing aliquots of DNA processed using the QIAshredder to those digested with RsaI or BsaJI prior to droplet digital PCR, we found that the copy numbers measured from the QIAshredded DNA tended to be greater than those measured from the digested DNA (average of 1.35-fold compared with BsaJI; P < 0.0001), even for inputs as high as 1.8 µg or dilution down to the single copy level

    BCG Δ<i>ureC</i>::<i>hly_hIL7</i> and BCG Δ<i>ureC</i>::<i>hly_hIL18</i> enhance antigen-specific Th1 responses.

    No full text
    <p>Flow cytometric analysis of CD40L-expressing antigen-specific CD4<sup>+</sup> T cell responses (<b>A</b>) and cytokine-producing CD40L<sup>+</sup>CD4<sup>+</sup> T cells (<b>B</b>) in the lungs, spleen and draining (inguinal) lymph nodes (dLNs) of vaccinated mice following <i>in vitro</i> re-stimulation with <i>M. tuberculosis</i> H37Rv whole cell lysate. Only comparisons made with BCG Δ<i>ureC</i>::<i>hly</i> are displayed. Shown are means ± SEM (n = 3 mice per group) analyzed using two-way ANOVA and Tukey’s post-hoc test; <i>*p<0.05</i>. Experiment was performed twice.</p

    Generation and validation of BCG Δ<i>ureC</i>::<i>hly</i>_<i>hIL7</i> and BCG Δ<i>ureC</i>::<i>hly</i>_<i>hIL18</i>.

    No full text
    <p><b>A</b>. Organisation of the cytokine expression cassette for stable transformation of BCG Δ<i>ureC</i>::<i>hly</i>. <b>B</b>. Confirmation of hIL-7 and hIL-18 gene presence (gDNA as template) and transcription (cDNA as template) in BCG Δ<i>ureC:hly_hIL7</i> or BCG Δ<i>ureC:hly_hIL18</i>, respectively using PCR or RT-PCR. <b>C</b>. Confirmation of hIL-18 and hIL-7 protein expression by the respective strains using ELISA. Experiments were performed twice with similar outcome.</p
    corecore